Insight into the Development of PET Radiopharmaceuticals for Oncology
While the development of positron emission tomography (PET) radiopharmaceuticals
closely follows that of traditional drug development, there are several key considerations in …
closely follows that of traditional drug development, there are several key considerations in …
Inverse electron demand Diels–Alder click chemistry for pretargeted PET imaging and radioimmunotherapy
SM Sarrett, O Keinänen, EJ Dayts, G Dewaele-Le Roi… - Nature protocols, 2021 - nature.com
Radiolabeled antibodies have shown promise as tools for both the nuclear imaging and
endoradiotherapy of cancer, but the protracted circulation time of radioimmunoconjugates …
endoradiotherapy of cancer, but the protracted circulation time of radioimmunoconjugates …
Treatment of Prostate Cancer with CD46-targeted 225Ac Alpha Particle Radioimmunotherapy
Purpose: Radiopharmaceutical therapy is changing the standard of care in prostate cancer
and other malignancies. We previously reported high CD46 expression in prostate cancer …
and other malignancies. We previously reported high CD46 expression in prostate cancer …
Immunotherapeutic targeting and PET imaging of DLL3 in small-cell neuroendocrine prostate cancer
Effective treatments for de novo and treatment-emergent small-cell/neuroendocrine (t-
SCNC) prostate cancer represent an unmet need for this disease. Using metastatic biopsies …
SCNC) prostate cancer represent an unmet need for this disease. Using metastatic biopsies …
CD46-Targeted Theranostics for PET and 225Ac-Radiopharmaceutical Therapy of Multiple Myeloma
Purpose: Multiple myeloma is a plasma cell malignancy with an unmet clinical need for
improved imaging methods and therapeutics. Recently, we identified CD46 as an …
improved imaging methods and therapeutics. Recently, we identified CD46 as an …
Molecular imaging of neuroendocrine prostate cancer by targeting delta-like ligand 3
JA Korsen, TM Kalidindi, S Khitrov… - Journal of Nuclear …, 2022 - Soc Nuclear Med
Treatment-induced neuroendocrine prostate cancer (NEPC) is a lethal subtype of castration-
resistant prostate cancer. Using the 89Zr-labeled delta-like ligand 3 (DLL3) targeting …
resistant prostate cancer. Using the 89Zr-labeled delta-like ligand 3 (DLL3) targeting …
Effective treatment of human breast carcinoma xenografts with single-dose 211At-labeled anti-HER2 single-domain antibody fragment
Y Feng, R Meshaw, XG Zhao, S Jannetti… - Journal of Nuclear …, 2023 - Soc Nuclear Med
Single-domain antibody fragments (sdAbs) are attractive for targeted α-particle therapy,
particularly with 211At, because of their rapid accumulation in tumor and clearance from …
particularly with 211At, because of their rapid accumulation in tumor and clearance from …
Imaging Tumor-Infiltrating Lymphocytes in Brain Tumors with [64Cu]Cu-NOTA-anti-CD8 PET
VL Nagle, KE Henry, CAJ Hertz, MS Graham… - Clinical Cancer …, 2021 - AACR
Purpose: Glioblastoma (GBM) is the most common malignant brain tumor in adults. Various
immunotherapeutic approaches to improve patient survival are being developed, but the …
immunotherapeutic approaches to improve patient survival are being developed, but the …
Lysine-directed site-selective bioconjugation for the creation of radioimmunoconjugates
SM Sarrett, C Rodriguez, G Rymarczyk… - Bioconjugate …, 2022 - ACS Publications
The synthesis of radioimmunoconjugates via the stochastic attachment of bifunctional
chelators to lysines can yield heterogeneous products with suboptimal in vitro and in vivo …
chelators to lysines can yield heterogeneous products with suboptimal in vitro and in vivo …
Targeted radionuclide therapy using auger electron emitters: the quest for the right vector and the right radionuclide
Auger electron emitters (AEEs) are attractive tools in targeted radionuclide therapy to
specifically irradiate tumour cells while sparing healthy tissues. However, because of their …
specifically irradiate tumour cells while sparing healthy tissues. However, because of their …